Evidence map›Paper›PMID 35669012›Full record

ArticleNeuro-oncology advances

Synthetic extracellular matrices and astrocytes provide a supportive microenvironment for the cultivation and investigation of primary pediatric gliomas.

Christopher M Rota, Alexander T Brown, Emily Addleson, Clara Ives, Ella Trumper, Kristine Pelton, Wei Pin Teh, Matthew J Schniederjan, Robert Craig Castellino, Sara Buhrlage and 4 more

Open access · goldAbstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Christopher M RotaDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-1790-958X
Alexander T BrownDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Emily AddlesonDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Clara IvesDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Ella TrumperDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Kristine PeltonDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Wei Pin TehDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Matthew J SchniederjanDepartment of Pathology, Emory University, Atlanta, Georgia, USA.
Robert Craig CastellinoDepartment of Pediatrics, Emory University, Atlanta, Georgia, USA.
Sara BuhrlageDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Douglas A LauffenburgerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Keith L LigonDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Linda G GriffithDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Rosalind A SegalDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-9850-8432
Dana-Farber Cancer Institute · USMassachusetts Institute of Technology · USEmory University · US

Funding

Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WENDY Beth LONDON · 2013 to 2026
$33.5M
Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI SCOTT Loren POMEROY, MUSTAFA SAHIN · 2021 to 2026
$9.4M
Spatial Considerations in Neuronal Survival SignalsR01NS050674 · NINDS · DANA-FARBER CANCER INSTITUTE · PI SEGAL, ROSALIND A. · 2005 to 2021
$5.9M
MYB family alterations in pediatric gliomasR01CA215489 · NCI · DANA-FARBER CANCER INST · PI BEROUKHIM, RAMEEN, LIGON, KEITH LLOYD · 2017 to 2021
$2.8M
Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine GliomasR01CA219943 · NCI · BROAD INSTITUTE, INC. · PI BEROUKHIM, RAMEEN, LIGON, KEITH LLOYD · 2017 to 2021
$2.5M
NCI NIH HHS P50 CA165962NCI NIH HHS R01 CA215489NCI NIH HHS R01 CA219943NICHD NIH HHS P50 HD105351NINDS NIH HHS R01 NS050674
6 · The paper itself

Abstract

Background: Pediatric gliomas comprise a diverse set of brain tumor entities that have substantial long-term ramifications for patient survival and quality of life. However, the study of these tumors is currently limited due to a lack of authentic models. Additionally, many aspects of pediatric brain tumor biology, such as tumor cell invasiveness, have been difficult to study with currently available tools. To address these issues, we developed a synthetic extracellular matrix (sECM)-based culture system to grow and study primary pediatric brain tumor cells. Methods: We developed a brain-like sECM material as a supportive scaffold for the culture of primary, patient-derived pediatric glioma cells and established patient-derived cell lines. Primary juvenile brainstem-derived murine astrocytes were used as a feeder layer to support the growth of primary human tumor cells. Results: We found that our culture system facilitated the proliferation of various primary pediatric brain tumors, including low-grade gliomas, and enabled ex vivo testing of investigational therapeutics. Additionally, we found that tuning this sECM material allowed us to assess high-grade pediatric glioma cell invasion and evaluate therapeutic interventions targeting invasive behavior. Conclusion: Our sECM culture platform provides a multipurpose tool for pediatric brain tumor researchers that enables both a wide breadth of biological assays and the cultivation of diverse tumor types.

Indexed as

diffuse midline glioma (DMG)juvenile pilocytic astrocytoma (JPA)pediatric low-grade gliomasynthetic extracellular matrixtumor cell invasion

Identifiers

PMID35669012
PMCPMC9159660
OpenAlexW4223640670

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.